Paul G. Ambrose

Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations � (2007)

A Gumbo, Arnold Louie, Weiguo Liu, David Brown, Paul G. Ambrose, Sujata M. Bhavnani, ...

Isoniazid, administered as part of combination antituberculosis therapy, is responsible for most of the early bactericidal activity (EBA) of the regimen. However, the emergence of Mycobacterium...

Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction (2003)

Ambrose, Paul G., Bhavnani, Sujata M., Cirincione, Brenda B., Piedmonte, Marion, Grasela, Thaddeus H.

Objectives: Recently, anecdotal reports via the FDA’s MedWatch reporting system have documented rare but serious hyperglycaemia in elderly patients receiving gatifloxacin. One possible factor...

Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction (2003)

Ambrose, Paul G., Bhavnani, Sujata M., Cirincione, Brenda B., Piedmonte, Marion, Grasela, Thaddeus H.

Objectives: Recently, anecdotal reports via the FDA's MedWatch reporting system have documented rare but serious hyperglycaemia in elderly patients receiving gatifloxacin. One possible factor...

Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction (2003)

Ambrose, Paul G., Bhavnani, Sujata M., Cirincione, Brenda B., Piedmonte, Marion, Grasela, Thaddeus H.

Objectives: Recently, anecdotal reports via the FDA's MedWatch reporting system have documented rare but serious hyperglycaemia in elderly patients receiving gatifloxacin. One possible factor...

Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team (2002)

Ronald N. Jones, Christopher M. Rubino, Sujata M. Bhavnani, Paul G. Ambrose

The use of fluoroquinolones for the treatment of community-acquired respiratory tract infection is increasing. Since for Streptococcus pneumoniae a ratio of the 24-h area under the concentration-time...

Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime (2002)

Ambrose, Paul G., Owens, Robert C., Garvey, Michael J., Jones, Ronald N.

Pseudomonas aeruginosa is one of the more common and clinically difficult-to-treat causes of hospital-acquired infections. Cefepime is a broad-spectrum cephalosporin with potent in vitro activity...

Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis (2000)

Mason, Edward O., Lamberth, Linda B., Kershaw, Nerisa L., Prosser, Barbara La T., Zoe, Annette, Ambrose, Paul G.

Ninety-two laboratories in the USA submitted isolates of Streptococcus pneumoniae to a single laboratory for susceptibility testing. Overall, 64% of 4489 isolates were susceptible to penicillin, 24%...

Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections

Ambrose, Paul G., Grasela, Dennis M., Grasela, Thaddeus H., Passarell, Julie, Mayer, Howard B., Pierce, Phillip F.

Fluoroquinolone antibiotic agents have demonstrated efficacy in the treatment of respiratory tract infections. This analysis was designed to examine the relationship between drug exposure, as...

Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team

Jones, Ronald N., Rubino, Christopher M., Bhavnani, Sujata M., Ambrose, Paul G.

The use of fluoroquinolones for the treatment of community-acquired respiratory tract infection is increasing. Since for Streptococcus pneumoniae a ratio of the 24-h area under the concentration-time...

Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections

Van Wart, Scott, Phillips, Luann, Ludwig, Elizabeth A., Russo, Rene, Gajjar, Diptee A., Bello, Akintunde, ...

Garenoxacin (T-3811ME, BMS-284756) is a novel, broad-spectrum des-F(6) quinolone currently under study for the treatment of community-acquired respiratory tract infections. This analysis assessed...

Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose

Fetterly, Gerald J., Ong, Christine M., Bhavnani, Sujata M., Loutit, Jeffrey S., Porter, Steven B., Morello, Lisa G., ...

Oritavancin is a novel glycopeptide currently being developed for the treatment of complicated skin and skin structure infections (cSSSI), including those caused by multidrug resistant gram-positive...

Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi

Booker, Brent M., Smith, Patrick F., Forrest, Alan, Bullock, Julie, Kelchlin, Pamela, Bhavnani, Sujata M., ...

Salmonella enterica serotype Typhi and nontyphoidal Salmonella remain major causes of morbidity and mortality worldwide. Ampicillin, trimethoprim-sulfamethoxazole, and chloramphenicol no longer...

Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem

Bhavnani, Sujata M., Hammel, Jeffrey P., Cirincione, Brenda B., Wikler, Matthew A., Ambrose, Paul G.

A doripenem population pharmacokinetic model and Monte Carlo simulations were utilized for dose regimen decision support for future clinical development. Simulation results predict that 500 mg of...

Comparison of Censored Regression and Standard Regression Analyses for Modeling Relationships between Antimicrobial Susceptibility and Patient- and Institution-Specific Variables

Hammel, Jeffrey P., Bhavnani, Sujata M., Jones, Ronald N., Forrest, Alan, Ambrose, Paul G.

In order to identify patients likely to be infected with resistant bacterial pathogens, analytic methods such as standard regression (SR) may be applied to surveillance data to determine patient- and...

Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia

Bhavnani, Sujata M., Passarell, Julie A., Owen, Joel S., Loutit, Jeffrey S., Porter, Steven B., Ambrose, Paul G.

Bloodstream infections due to antimicrobial-resistant Staphylococcus aureus occur with increasing frequency and represent an important cause of morbidity and mortality. To date, the evaluation of...

Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections

Ambrose, Paul G., Grasela, Dennis M., Grasela, Thaddeus H., Passarell, Julie, Mayer, Howard B., Pierce, Phillip F.

Fluoroquinolone antibiotic agents have demonstrated efficacy in the treatment of respiratory tract infections. This analysis was designed to examine the relationship between drug exposure, as...

Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team

Jones, Ronald N., Rubino, Christopher M., Bhavnani, Sujata M., Ambrose, Paul G.

The use of fluoroquinolones for the treatment of community-acquired respiratory tract infection is increasing. Since for Streptococcus pneumoniae a ratio of the 24-h area under the concentration-time...

Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections

Van Wart, Scott, Phillips, Luann, Ludwig, Elizabeth A., Russo, Rene, Gajjar, Diptee A., Bello, Akintunde, ...

Garenoxacin (T-3811ME, BMS-284756) is a novel, broad-spectrum des-F(6) quinolone currently under study for the treatment of community-acquired respiratory tract infections. This analysis assessed...

Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose

Fetterly, Gerald J., Ong, Christine M., Bhavnani, Sujata M., Loutit, Jeffrey S., Porter, Steven B., Morello, Lisa G., ...

Oritavancin is a novel glycopeptide currently being developed for the treatment of complicated skin and skin structure infections (cSSSI), including those caused by multidrug resistant gram-positive...

Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi

Booker, Brent M., Smith, Patrick F., Forrest, Alan, Bullock, Julie, Kelchlin, Pamela, Bhavnani, Sujata M., ...

Salmonella enterica serotype Typhi and nontyphoidal Salmonella remain major causes of morbidity and mortality worldwide. Ampicillin, trimethoprim-sulfamethoxazole, and chloramphenicol no longer...

Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem

Bhavnani, Sujata M., Hammel, Jeffrey P., Cirincione, Brenda B., Wikler, Matthew A., Ambrose, Paul G.

A doripenem population pharmacokinetic model and Monte Carlo simulations were utilized for dose regimen decision support for future clinical development. Simulation results predict that 500 mg of...

Comparison of Censored Regression and Standard Regression Analyses for Modeling Relationships between Antimicrobial Susceptibility and Patient- and Institution-Specific Variables

Hammel, Jeffrey P., Bhavnani, Sujata M., Jones, Ronald N., Forrest, Alan, Ambrose, Paul G.

In order to identify patients likely to be infected with resistant bacterial pathogens, analytic methods such as standard regression (SR) may be applied to surveillance data to determine patient- and...

Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia

Bhavnani, Sujata M., Passarell, Julie A., Owen, Joel S., Loutit, Jeffrey S., Porter, Steven B., Ambrose, Paul G.

Bloodstream infections due to antimicrobial-resistant Staphylococcus aureus occur with increasing frequency and represent an important cause of morbidity and mortality. To date, the evaluation of...

Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations▿

Gumbo, Tawanda, Louie, Arnold, Liu, Weiguo, Brown, David, Ambrose, Paul G., Bhavnani, Sujata M., ...

Isoniazid, administered as part of combination antituberculosis therapy, is responsible for most of the early bactericidal activity (EBA) of the regimen. However, the emergence of Mycobacterium...

Evaluation of Tigecycline Penetration into Colon Wall Tissue and Epithelial Lining Fluid Using a Population Pharmacokinetic Model and Monte Carlo Simulation▿

Rubino, Christopher M., Ma, Lei, Bhavnani, Sujata M., Korth-Bradley, Joan, Speth, John, Ellis-Grosse, Evelyn, ...

The objective of these analyses was to assess the penetration of tigecycline into colon wall tissue and epithelial lining fluid (ELF). The analyses included data from subjects without infection...

Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model▿

Ambrose, Paul G., Forrest, Alan, Craig, William A., Rubino, Chistopher M., Bhavnani, Sujata M., Drusano, George L., ...

We determined the pharmacokinetic-pharmacodynamic (PK-PD) measure most predictive of gatifloxacin efficacy and the magnitude of this measure necessary for survival in a murine Bacillus anthracis...